{"news_desk": "Business", "print_page": "5", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By STEVEN DAVIDOFF SOLOMON", "person": [{"middlename": "Davidoff", "firstname": "Steven", "lastname": "SOLOMON", "rank": 1, "role": "reported", "organization": ""}]}, "abstract": "Steven Davidoff Solomon Deal Professor column runs through various explanations for turmoil at Valeant Pharmaceuticals International, once Wall Street darling.", "type_of_material": "News", "word_count": "1271", "lead_paragraph": "Reasons given for the turmoil at Valeant Pharmaceuticals include its cuts in research and development, its drug pricing and investors\u2019 influence.", "pub_date": "2016-03-30T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Explaining Valeant: The Main Theories", "content_kicker": "Deal Professor", "print_headline": "Explaining Valeant: The Main Theories", "kicker": "Deal Professor"}, "snippet": "Reasons given for the turmoil at Valeant Pharmaceuticals include its cuts in research and development, its drug pricing and investors\u2019 influence.", "multimedia": [{"height": 126, "url": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 608, "url": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "608", "xlarge": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/03/30/business/dealbook/explaining-valeant-the-main-theories.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "N", "value": "McKinsey & Co", "name": "organizations"}, {"rank": "3", "is_major": "N", "value": "Stocks and Bonds", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "56fb020f38f0d816b6b7e254", "source": "The New York Times"}